Cartesian Competitors
| RNAC Stock | 7.64 0.06 0.79% |
Cartesian Therapeutics vs Genfit SA Correlation
Very good diversification
The correlation between Cartesian Therapeutics and GNFT is -0.39 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cartesian Therapeutics and GNFT in the same portfolio, assuming nothing else is changed.
Moving together with Cartesian Stock
The current year's Return On Equity is expected to grow to 10.76, whereas Return On Tangible Assets are forecasted to decline to (0.40). At present, Cartesian Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 263.7 M, whereas Non Currrent Assets Other are forecasted to decline to about 1.3 M.Cartesian Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Cartesian Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Cartesian and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Cartesian Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cartesian Stock performing well and Cartesian Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cartesian Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EPRX | 2.99 | 0.63 | 0.19 | 0.52 | 2.90 | 6.98 | 24.61 | |||
| IVA | 4.16 | 0.64 | 0.08 | 0.88 | 6.78 | 10.82 | 34.91 | |||
| NAUT | 5.96 | 1.30 | 0.18 | (26.18) | 5.59 | 16.32 | 53.15 | |||
| OBIO | 3.73 | (0.02) | 0.02 | 0.06 | 3.96 | 10.17 | 19.34 | |||
| MDWD | 1.79 | (0.17) | 0.00 | (0.33) | 0.00 | 3.79 | 14.07 | |||
| AARD | 3.92 | 0.24 | 0.08 | 0.15 | 4.38 | 9.25 | 36.39 | |||
| FENC | 2.05 | (0.18) | 0.00 | (0.44) | 0.00 | 4.19 | 17.84 | |||
| AVTX | 3.64 | (0.06) | 0.00 | (0.04) | 0.00 | 6.93 | 25.25 | |||
| NTHI | 5.61 | (0.21) | 0.01 | 0.03 | 7.67 | 9.99 | 41.97 | |||
| GNFT | 3.17 | 0.68 | 0.12 | (1.09) | 3.86 | 7.34 | 25.18 |
Cross Equities Net Income Analysis
Compare Cartesian Therapeutics and related stocks such as Eupraxia Pharmaceuticals, Inventiva Sa, and Nautilus Biotechnology Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IVA | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.5 M) | (8.8 M) | (7 M) | (17.2 M) | (33.6 M) | (30.2 M) | (31.6 M) | (49.6 M) | (54.3 M) | (110.4 M) | (184.2 M) | (165.8 M) | (157.5 M) |
| NAUT | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | (9.6 M) | (15.6 M) | (50.3 M) | (57.9 M) | (63.7 M) | (70.8 M) | (63.7 M) | (60.5 M) |
| OBIO | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (23 M) | (33.6 M) | (49.1 M) | (61 M) | (54.9 M) | (57.7 M) |
| MDWD | (6.2 M) | (6.2 M) | 10.9 M | (15.4 M) | (18.9 M) | (22.1 M) | (18.9 M) | (22.1 M) | (1.1 M) | 5 M | (9.2 M) | (13.6 M) | (19.6 M) | (6.7 M) | (30.2 M) | (27.2 M) | (25.8 M) |
| AARD | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (7.2 M) | (20.6 M) | (18.5 M) | (19.5 M) |
| FENC | (1.6 M) | 4.7 M | (5.2 M) | 1.8 M | (2.2 M) | (659 K) | (2.8 M) | (7 M) | (9.9 M) | (12.5 M) | (18.1 M) | (17.2 M) | (22.8 M) | (16 M) | (436 K) | (392.4 K) | (412 K) |
| AVTX | (10.5 M) | (10.5 M) | (10.5 M) | (13 M) | (16.1 M) | (10.5 M) | (16.5 M) | 11.9 M | (40.1 M) | (16.1 M) | (63.5 M) | (84.4 M) | (41.7 M) | (31.5 M) | (35.1 M) | (31.6 M) | (33.2 M) |
| NTHI | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3 M) | (14.9 M) | (11.9 M) | (10.7 M) | (11.2 M) |
| GNFT | 2.2 M | (9.7 M) | (5.4 M) | (12.7 M) | (17 M) | (17.1 M) | (33.7 M) | (58.6 M) | (79.5 M) | (65.1 M) | (101.2 M) | 67.3 M | (23.7 M) | (28.9 M) | 1.5 M | 1.4 M | 1.4 M |
Cartesian Therapeutics and related stocks such as Eupraxia Pharmaceuticals, Inventiva Sa, and Nautilus Biotechnology Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cartesian Therapeutics financial statement analysis. It represents the amount of money remaining after all of Cartesian Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Cartesian Therapeutics Competitive Analysis
The better you understand Cartesian Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Cartesian Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Cartesian Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Cartesian Therapeutics Competition Performance Charts
Five steps to successful analysis of Cartesian Therapeutics Competition
Cartesian Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Cartesian Therapeutics in relation to its competition. Cartesian Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Cartesian Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Cartesian Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Cartesian Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Cartesian Therapeutics position
In addition to having Cartesian Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hybrid Mix Funds Thematic Idea Now
Hybrid Mix Funds
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cartesian Therapeutics Correlation with its peers. For information on how to trade Cartesian Stock refer to our How to Trade Cartesian Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cartesian Therapeutics. If investors know Cartesian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cartesian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth 0.168 | Return On Assets |
The market value of Cartesian Therapeutics is measured differently than its book value, which is the value of Cartesian that is recorded on the company's balance sheet. Investors also form their own opinion of Cartesian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cartesian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cartesian Therapeutics' market value can be influenced by many factors that don't directly affect Cartesian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cartesian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cartesian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cartesian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.